IQVIA (NYSE:IQV – Get Free Report) and Bruker (NASDAQ:BRKR – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability.
Volatility and Risk
IQVIA has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. Comparatively, Bruker has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500.
Profitability
This table compares IQVIA and Bruker’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IQVIA | 8.05% | 30.02% | 6.52% |
| Bruker | -3.82% | 13.76% | 5.47% |
Institutional & Insider Ownership
89.6% of IQVIA shares are held by institutional investors. Comparatively, 79.5% of Bruker shares are held by institutional investors. 1.7% of IQVIA shares are held by company insiders. Comparatively, 27.2% of Bruker shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares IQVIA and Bruker”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| IQVIA | $17.31 billion | 2.52 | $1.36 billion | $8.23 | 32.16 |
| Bruker | $3.44 billion | 2.72 | -$8.60 million | ($1.10) | -55.54 |
IQVIA has higher revenue and earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current recommendations for IQVIA and Bruker, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IQVIA | 1 | 2 | 16 | 2 | 2.90 |
| Bruker | 1 | 6 | 5 | 2 | 2.57 |
IQVIA presently has a consensus price target of $294.21, suggesting a potential upside of 11.14%. Bruker has a consensus price target of $60.57, suggesting a potential downside of 0.86%. Given IQVIA’s stronger consensus rating and higher probable upside, analysts plainly believe IQVIA is more favorable than Bruker.
Summary
IQVIA beats Bruker on 11 of the 14 factors compared between the two stocks.
About IQVIA
IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.
About Bruker
Bruker develops and manufactures scientific instruments and analytical technologies used to study biological, chemical and physical materials. Its products support research and testing in areas including life sciences, pharmaceuticals, biotechnology, materials science, chemicals and clinical diagnostics. The company’s offerings include nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray and microscopy instruments, and infrared and Raman spectroscopy solutions.
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
